Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2018-10-19 Regulatory Filings
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech to present Phase I dose escalation results at ESMO
Regulatory Filings Classification · 95% confidence The document is a short announcement from PCI Biotech stating that they will present Phase I dose escalation results at the ESMO 2018 Congress. It details the date, location, and contact information, and mentions where the poster will be available online. Since the document is short (3421 chars) and primarily serves to announce the presentation of results at a conference rather than being the full report or presentation itself, it fits the description of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it is specifically announcing the publication/presentation of scientific results, RPA is a strong candidate, but since it is a general announcement about presenting data, and not explicitly announcing the release of a formal financial report, RNS (Regulatory Filings - general regulatory announcements) is a safer fallback, although RPA is also plausible if we interpret 'report' broadly. However, looking at the definitions, this is an announcement about presenting scientific data at a medical conference, which is often categorized under general regulatory news or investor relations updates that don't fit specific financial report codes. Since it's not a financial report (10-K, IR, ER) or a formal presentation (IP), and it's an announcement, RNS (Regulatory Filings) is the most appropriate general category for non-standard announcements, or potentially LTR if it were a legal update, but it is not. Given the context of corporate filings, this type of scientific update announcement often falls under general regulatory news. I will classify it as RNS as it is a general regulatory announcement about company activity/data presentation.
2018-10-19 English
PCI Biotech: Exercise of employee share options, mandatory noticifation of trade and resolution to increase share capital
Remuneration Information Classification · 99% confidence The document explicitly details two main events: 1) The exercise of employee share options by insiders, including a mandatory notification of trade by the CBDO (Gaël L’Hévéder), and 2) A resolution by the Board of Directors to increase the share capital by issuing 170,000 new shares following the option exercise. The content directly relates to insider transactions (Director's Dealing) and changes in the share structure (Share Issue/Capital Change). Since the document covers both insider trading notification (DIRS) and a capital increase (SHA), I must choose the most fitting primary category. The mandatory notification of trade by a primary insider regarding their personal transaction (selling shares to cover costs) strongly aligns with 'Director's Dealing' (DIRS). However, the resolution to increase share capital is also a core component. Given the structure, which starts with the insider transaction and then details the resulting capital increase, and considering that 'SHA' covers share issues/capital changes, while 'DIRS' covers director dealings, both are highly relevant. Since the document is a formal announcement covering both aspects, and the capital increase is a direct consequence of the options exercised by insiders, I will prioritize the 'Share Issue/Capital Change' (SHA) as it describes the corporate action taken, or 'DIRS' for the insider trade notification. Looking at the definitions, 'DIRS' is for personal share transactions by directors, and 'SHA' is for share issue/capital change. Since both are present, and the document is a formal regulatory disclosure (implied by the reference to Norwegian Securities Trading Act), I will check if there is a better fit. The document is a direct announcement of corporate action (capital increase) and insider activity. 'SHA' (Share Issue/Capital Change) seems slightly broader and covers the resolution to issue new shares. However, the explicit mention of 'mandatory notification of trade' for the insider makes 'DIRS' very strong. In cases where insider trading is explicitly mentioned alongside a corporate action, 'DIRS' often takes precedence if the trade is the primary focus. Here, the capital increase is also a major component. Let's re-evaluate the definitions. The document is a formal announcement detailing both insider trades and a capital increase. Since the capital increase (issuing 170,000 new shares) is a direct corporate action resulting from the options, 'SHA' is appropriate. If the focus was purely on the insider's sale, 'DIRS' would be better. Given the dual nature, and that the capital increase is a formal resolution, I will classify it as 'SHA'. If 'SHA' is not the best fit, 'RNS' would be the fallback. Upon review, the document is a direct announcement of a capital increase resulting from option exercises, which fits 'SHA' (Share Issue/Capital Change). It also contains insider dealing information, which fits 'DIRS'. Since the capital increase is a formal resolution by the Board, 'SHA' is a strong fit for the corporate action described. I will select SHA.
2018-10-17 English
PCI Biotech: Exercise of employee share options, mandatory noticifation of trade and resolution to increase share capital
Director's Dealing Classification · 100% confidence The document explicitly details the 'Exercise of employee share options', a 'mandatory notification of trade' by a primary insider (CBDO), and a 'resolution to increase the share capital' by issuing new shares. These actions directly relate to changes in the company's share structure and insider transactions. The options exercise leads to a capital increase (SHA), and the insider's subsequent sale/holding change is related to insider dealing (DIRS). Since the document covers both the issuance of new shares following option exercises (SHA) and the mandatory notification of a director's trade (DIRS), it fits best under the category dealing with capital changes or share issues. 'Share Issue/Capital Change' (SHA) covers the resolution to increase share capital by issuing new shares. While DIRS is also relevant, the primary corporate action announced is the capital increase resulting from the options exercise. Given the options, SHA is the most encompassing fit for the capital structure change announced, although POS (Transaction in Own Shares) could also be considered if the options exercise is viewed as a form of share issuance, but SHA is more precise for a formal capital increase resolution. However, looking closely at the definitions, DIRS covers personal share transactions by directors, and SHA covers new share issues. Since the document is a mandatory notification covering both the insider trade (DIRS) and the resulting capital increase (SHA), and it is a short regulatory announcement, I will prioritize the most specific corporate action related to the capital structure change, which is the resolution to increase share capital. Alternatively, since it is a mandatory notification of trade by an insider, DIRS is highly relevant. Given the dual nature, and the fact that the document is a short regulatory notice, I will check if there is a better fit. Since the core event is the exercise of options leading to a capital increase, SHA is strong. However, the document explicitly states it is a 'mandatory notification of trade' for the insider's sale. Let's re-evaluate the options: SHA (Share Issue/Capital Change) covers the capital increase. DIRS (Director's Dealing) covers the insider trade. Since both are present, and this is a regulatory filing, I will select the category that best describes the overall nature of the announcement, which is a mandatory disclosure triggered by insider activity and subsequent capital adjustment. Given the explicit mention of insider trade and the resulting capital increase, SHA seems slightly more comprehensive for the corporate action taken by the Board, but DIRS is also very strong. Since the document is short and appears to be a regulatory disclosure, and it details both insider trading and capital change, I will classify it as SHA as the capital increase is a formal resolution taken by the Board based on the options exercised. If the focus was purely on the insider's sale, DIRS would be chosen. Since the capital increase resolution is a major component, SHA is selected. The document length is short (2445 chars) and it is a formal notice, not a full report, so RPA/RNS is not appropriate as SHA/DIRS are specific categories.
2018-10-17 English
Disclosure of large shareholding
Major Shareholding Notification Classification · 98% confidence The document explicitly discusses a change in shareholding percentage ('Myrlid AS has become the owner of shares representing more than 5 % of the share capital') following a rights issue. This directly relates to notifications about changes in significant share ownership levels, crossing ownership thresholds. This aligns perfectly with the definition for Major Shareholding Notification (MRQ). The document is short and contains the core notification, not an announcement of a separate report.
2018-10-10 English
Disclosure of large shareholding
Major Shareholding Notification Classification · 98% confidence The document is titled "Disclosure of large shareholding" and explicitly states that a party (Myrlid AS) has subscribed to new shares, resulting in their ownership crossing the 5% threshold of the company's share capital. This directly relates to changes in significant share ownership levels, which matches the definition for Major Shareholding Notification (MRQ). The document length is very short (1031 chars), but the content is the notification itself, not an announcement *about* a notification, thus MRQ is more specific than RPA or RNS.
2018-10-10 English
PCI Biotech: Capital increase registered and listing of new shares
Capital/Financing Update Classification · 98% confidence The document explicitly discusses the completion of a 'fully underwritten rights issue of 12,000,000 new shares' and the subsequent registration of the 'share capital increase' in the Norwegian Register of Business Enterprises. This action directly relates to changes in the company's capital structure and the issuance of new shares following a financing activity (the Rights Issue). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). While it involves shares, it is a notification of the completion of a capital raising event, not just a routine buyback (POS) or a general share issue announcement (SHA), but specifically a financing/capital structure change event.
2018-10-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.